Kiniksa Pharmaceuticals International (KNSA) EBIT Growth (1y) (2018 - 2026)
Kiniksa Pharmaceuticals International (KNSA) EBIT Growth (1y) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | -150.77% |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | -10.00% |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -0.93% |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | -9.25% |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | -97.30% |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 4.05% |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 12.73% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Kiniksa Pharmaceuticals International | 6.14 Bn | 5.61 Bn | 220.03 Mn | 34.89% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 34.89% |
| Mar 31, 2026 | 120.52% |
| Dec 31, 2025 | 202.43% |
| Sep 30, 2025 | 348.72% |
| Jun 30, 2025 | 17,330.77% |
| Mar 31, 2025 | 180.23% |
| Dec 31, 2024 | -23,925.93% |
| Sep 30, 2024 | 11.61% |
| Jun 30, 2024 | 96.29% |
| Mar 31, 2024 | -47.75% |
| Dec 31, 2023 | -98.66% |
| Sep 30, 2023 | -123.54% |
| Jun 30, 2023 | 83.72% |
| Mar 31, 2023 | 51.99% |
| Dec 31, 2022 | 116.74% |
| Sep 30, 2022 | 251.35% |
| Jun 30, 2022 | 52.24% |
| Mar 31, 2022 | 52.68% |
| Dec 31, 2021 | 31.70% |
| Sep 30, 2021 | 29.04% |